你好!欢迎访问 登录|立即注册

0576-88813233

|
当前位置:科瑞产品

吡仑帕奈 PeraMpanel

吡仑帕奈 PeraMpanel 380917-97-5
规格 价格 库存 数量
在线咨询 大包装询价 加入购物车
如您需要更多数量的报价,请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您,谢谢!
产品信息
产品名称:吡仑帕奈 PeraMpanel 纯度:98% min
CAS NO:380917-97-5 溶解度:
分子式:C23H15N3O 包装:可按客户要求包装
分子量:349.385 贮存:-20℃
质量控制
备注说明

Perampanel is a selective noncompetitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. Perampanel was found to be effective in the treatment of refractory partial-onset seizures in three pivotal (Phase 3) clinical trials and has been approved for marketing under the brand name Fycompa by the European Medicines Agency. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older. Perampanel is discontinued.



参考文献

1: Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016 Mar;133(3):160-72. doi: 10.1111/ane.12529. Review. PubMed PMID: 26506904; PubMed Central PMCID: PMC4738453.

2: Glauser T, Laurenza A, Yang H, Williams B, Ma T, Fain R. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis. Epilepsy Res. 2016 Jan;119:34-40. doi: 10.1016/j.eplepsyres.2015.11.014. PubMed PMID: 26656783.

版权所有 Copyright(C) 2018-2021 台州市科瑞生物技术有限公司

技术支持:kerui  浙ICP备09021343号
公司所列产品中涉及到专利,只供研发使用,不做销售;管制产品将严格遵守中国法律和购买客户国法律的规定销售,所有产品都不适用于人用 如被销售到构成专利侵权的国家,则相应的一切风险将由买方承担。